Speciality pharmaceutical firm IS Pharma has said it will buy Switzerland-based Helsinn Healthcare's Irish commercial operations for €4.4m to expand its business in Europe.
The Dublin-based Irish unit of Helsinn comprises a portfolio of hospital and generic products.
'This acquisition will give IS Pharma a direct sales presence in Ireland, which will be used to market IS Pharma's existing portfolio of products,' the company said.
IS Pharma has also bought the UK and Irish licensing rights of fixed dose combination of netupitant and palonosetron (NETU-PALO FDC), which is a treatment in development for the prevention of nausea and vomiting related to chemotherapy.
The company will pay Helsinn €.05m on signing the licensing agreement, with further payments to a maximum of €2.5m linked to regulatory and launch milestones.
